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“Personal” or “School” domain was eliminated, indicat-
ing the questionnaire is sensitive to the cultural and social
differences between Asian and European cultures. The re-
liability of the instrument as measured by Cronbach’s
alpha for the six domains for the diabetics ranges from
0.31 to 0.75.
CONCLUSION: Although the results appear improba-
ble, they agree with the cultural and social characteristics
of Singapore where the educational system is highly
stressful. Parents of diabetic children may have lower ex-
pectations of their children due to their condition, and
hence the perceived better QOL among the diabetic chil-
dren. However, more data needs to be collected to con-
firm this observation. *Maximum possible score of 100.
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OBJECTIVE: To highlight the effects incurred in the
pharmaco-utilization and in the total expenses for dys-
peptic patients by the introduction of a disease-manage-
ment guideline.
METHODS: A retrospective reading of an administrative
billing database in the Ravenna Local Health Unit was
performed for all health-assisted subjects of 10 GPs who
had previously developed and agreed to a clinical guide-
line to manage dyspeptic patients (Dyspro GPs) as well as
by a group of 30 self-regulated GPs (Control GPs). The
latter group was selected ex post so as not to be signifi-
cantly different from the former in terms of personal and
patient characteristics. According to anti-dyspeptic treat-
ment, patients were grouped as having had or not pre-
scriptions between 01/01/1999 and 12/31/1999. Dyspep-
tic subjects were divided as having had or not an earlier
anti-dyspeptic treatment (new users/users). The follow-up
period lasted 365 days.
RESULTS: A total of 51,904 subjects were enrolled, of
which 23.1% were enrolled by the Dyspro GPs and
76.9% by the Control GPs. The percentage of dyspeptic
patients accounted for 17.6% and 15.0% respectively of
subjects enrolled by the Dyspro GPs and the Control
GPs. The average age of dyspeptic patients was 57.1 
18.6 years and 57.3  18.9 years (p  ns) and the per-
centage of males was 40.1 and 42.0 (p  ns), respectively
in the Dyspro GPs and Control GPs groups. The average
drug costs for new users (35.76 vs 38.56) and users
(107.51 vs 113.73) was higher as was the average
hospitalization cost for new users (65.78 vs 70.84)
and users (61.13 vs 87.40) in patients enrolled by the
Control GPs. Casualty department access and gas-
troscopies were not different among patients enrolled by
the physician groups.
DISCUSSION: Pharmaceutical and hospital expenditures
decreased as a consequence of the introduction of a dis-
ease-management guideline.
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OBJECTIVE: Rabeprazole (Pariet) is a new proton-pump
inhibitor, which offers fast and consistent acid control.
Randomized controlled studies showed that rabeprazole
in active peptic ulcer is comparable to omeprazole and
more effective than ranitidine. We performed economic
evaluations of rabeprazole, omeprazole and ranitidine in
active gastric and duodenal ulcers.
METHODS: A decision tree model (DATA 3.0 Treeage
Software Inc.) was applied for retrospective analysis of
peptic ulcer healing rate in controlled clinical trials of the
three drugs. Direct costs of standard treatment in a hospi-
tal setting (six and four weeks for gastric and duodenal
ulcers respectively) were calculated. They included hospi-
tal bills, investigations and drug-acquisition costs. Cost-
minimization and cost-effectiveness analyses were used to
evaluate rabeprazole vs. omeprazole and rabeprazole vs
ranitidine respectively. To calculate the incremental cost-
effectiveness ratio, we utilized the rate of improvement in
well-being after two weeks of treatment.
RESULTS: The direct costs of rabeprazole and ranitidine
in active duodenal ulcer were comparable ($261,21 vs
$263,28), but the proton pump inhibitor was signifi-
cantly more cost-effective than the H2-blocker (incre-
mental cost-effectiveness ratio 0,43 vs 4,66). The differ-
ence was due to the higher healing rate and faster effect
of rabeprazole. The direct costs of rabeprazole and ome-
prazole in active duodenal and gastric ulcer were
$248,21 vs $266,94 and $311,53 vs $332,77 respec-
tively. The difference was due to lower acquisition cost of
rabeprazole.
CONCLUSION: Rabeprazole may offer economic ad-
vantages over omeprazole and ranitidine in hospital
treatment of active gastric and duodenal ulcers.
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